Pfizer has retracted a 2009 Journal of Clinical Oncology study purporting to show a benefit of their experimental drug for lung cancer figitumumab after discovering that its clinical lead on the project had done analyses improperly.
Here’s the text of the notice: Continue reading Pfizer retracts study of experimental cancer treatment figitumumab for incorrect analyses
The retraction counts keep mounting for two Retraction Watch frequent flyers.
First, Diederik Stapel’s 26th retraction, according to our count. Psychologist Stapel admitted to making up data in dozens of studies, and is also facing a criminal inquiry for misuse of funds.
Here’s the notice: Continue reading Lemus, Stapel each rack up another retraction
A bit of intellectual property indiscretion has led to the retraction of a paper by Korean scientists. Although the details are fuzzy, several of the authors are affiliated with a Korean pharma company called SK.
The paper, “A Novel Carbamoyloxy Arylalkanoyl Arylpiperazine Compound (SKL-NP) Inhibits Hyperpolarization-Activated Cyclic Nucleotide-Gated (HCN) Channel Currents in Rat Dorsal Root Ganglion Neurons,” was published in the The Korean Journal of Physiology & Pharmacology earlier this year.
According to the retraction notice: Continue reading Loose lips sink paper on company’s experimental pain drug
Monica Acalovschi is serious about ridding the literature of duplicate publications.
That would seem to be the message of two new retraction notices in the Journal of Gastrointestinal and Liver Diseases, which Acalovschi edits — two retractions that join another for similar reasons, which we covered earlier this year.
Here are the notices, from the June issue of the journal (but which were just indexed by Medline):
For “Intestinal Pseudo-obstruction – a Rare Condition with Heterogeneous Etiology and Unpredictable Outcome. A Case Report:” Continue reading Gastro journal continues tough stance on duplication, with two new retractions
A prominent researcher at the University of Florida is under federal investigation for research misconduct and has lost at least one paper as a result of the fraud.
The researcher, Nasser Chegini, was a professor of obstetrics and gynecology at the U of Florida until about six months ago, when he retired, according to the chair’s office. Nasser has received at least $4 million in federal grant funding, according to the university.
The retracted paper, “MicroRNA 21: response to hormonal therapies and regulatory function in leiomyoma, transformed leiomyoma and leiomyosarcoma cells,” was published in 2010 by Molecular Human Reproduction. The authors were Qun Pan and Xiaoping Luo and Chegini.
As the notice explains: Continue reading ORI investigating University of Florida ob-gyn researcher accused of misconduct
Plasma Processes and Polymers has retracted a paper it published in March 2012 for what it describes as a “possible breach of ethics.”
That certainly sounds bad — if inconclusive — but the authors maintain the whole thing was a simple misunderstanding.
The article, “Plasma Acid: Water Treated by Dielectric Barrier Discharge,” came from the lab of Gary Friedman, a physicist at Drexel University in Philadelphia. The first, and corresponding, author was Natalie Shainsky, an award-winning graduate student at the school.
As the notice states: Continue reading Authors dispute ethical lapse in case of double physics publication that wasn’t
A difficult authorship dispute, involving two journals and at least two continents, has led to an Expression of Concern in the Brazilian Journal of Rheumatology.
Here’s the Expression of Concern: Continue reading Bitter authorship issues prompt Expression of Concern in rheumatology journal
The authors of a study on cancer incidence and survival in the Dutch migrant community have retracted it after realizing they’d made some errors that significantly affected the results.
But in what seems like an appropriate reward for coming forward, the newly analyzed data, with additional information, will be part of a forthcoming paper in another journal by the same authors.
The original retrospective study came out in May 2011 in the European Journal of Cancer Prevention and found that risk and survival of breast and stomach cancers differed depending on the person’s mother country. The problem was that the study jumbled up many of the participants’ homelands during the analysis.
The authors issued the following retraction: Continue reading Jumbled analysis leads to retraction of cancer study — but also another paper
The journal Neuroscience has retracted a 2011 paper by an alcohol researcher from the United Arab Emirates, who apparently conducted some mouse studies without the blessing of his institution’s animal ethics officials. At least, that’s what the retraction notice would have us believe.
The paper in question, “The pre-synaptic metabotropic glutamate receptor 7 “mGluR7” is a critical modulator of ethanol sensitivity in mice,” by Amine Bahi, was published in December 2011 and cited three times (twice by the author), according to Thomson Scientific’s Web of Knowledge. But as the notice explains:
A journal has retracted a 2005 paper by a group of physiologists at the University of Toronto after it became clear that the work duplicated five other articles by the same researchers.
Here’s the notice in Neuroscience & Biobehavioral Reviews for “Maternal adversity, glucocorticoids and programming of neuroendocrine function and behaviour:” Continue reading Duplication forces retraction of paper on effects of prenatal environment on behavior